Ken Griffin Celcuity Inc. Put Options Transaction History

Citadel Advisors LLC

6 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	BUY	$13.98 - $19.15 $41,940 - $57,449	3,000 New	3,000 $44,000
Q1 2024 May 15, 2024	BUY	$13.74 - $21.6 $54,960 - $86,400	4,000 New	4,000 $86,000
Q3 2023 Nov 14, 2023	SELL	$8.96 - $10.75 $13,440 - $16,125	-1,500 Reduced 93.75%	100 $0
Q2 2023 Aug 14, 2023	BUY	$9.39 - $12.18 $10,329 - $13,398	1,100 Added 220.0%	1,600 $17,000
Q1 2023 May 15, 2023	BUY	$9.4 - $12.82 $1,880 - $2,564	200 Added 66.67%	500 $5,000
Q4 2022 Feb 14, 2023	BUY	$7.55 - $14.01 $2,265 - $4,203	300 New	300 $4,000

107

30.3M

30.8K

152K

Ticker CELC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 14,941,300
Market Cap $187M
Description
Celcuity Inc., a clinical stage biotechnology company, focuses on the development of molecularly targeted therapies for cancer patients in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therap...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.